EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma

Johnny Duerinck iD, Louise Lescrauwaet, Iris Dirven, Jacomi Del'haye, Latoya Stevens, Xenia Geeraerts, Freya Vaeyens, Wietse Geens, Stefanie Brock, Anne-Marie Vanbinst, Hendrik Everaert, Ben Caljon und 6 weitere

Neuro-Oncology · 05.12.2024 · 26 (12) · 2208-2221

DOI: 10.1093/neuonc/noae177 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 16.10.2024. Verfasst von Johnny Duerinck und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Excellence of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 and CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates the safety and feasibility of intraoperative intracerebral (iCer) and postoperative intracavitary (iCav) nivolumab (NIVO) ± ipilimumab (IPI) treatment following maximal safe resection (MSR) in rHGG. Materials and methods Patients received 10 mg IV NIVO within 24 h before surgery, followed by MSR, iCer 5 mg IPI and 10 mg NIVO, and Ommaya catheter placement in the resection cavity. Biweekly postoperative iCav administrations of 1–5–10 mg NIVO (cohort 4) or 10 mg NIVO plus 1–5–10 mg IPI (cohort 7) were combined with 10 mg IV NIVO for 11 cycles.

Results

42 rHGG patients underwent MSR with iCer NIVO + IPI. 16 pts were treated in cohort 4 (postoperative iCav NIVO at escalating doses) while 28 patients were treated in cohort 7 (intra and postoperative iCav NIVO and escalating doses of IPI). The most common TRAE was fatigue; no grade 5 AE occurred. Dose-limiting toxicity was grade 3 neutrophilic pleocytosis (4 pts) receiving iCav NIVO plus 5 or 10 mg IPI. PFS and OS did not significantly differ between cohorts (median OS: 42 [95% CI 26–57] vs. 35 [29–40] weeks; 1-year OS rate: 37% vs. 29%). Baseline B7–H3 expression significantly correlated with worse survival. OS compared favorably to a historical pooled cohort (n = 469) of Belgian rHGG pts treated with anti-VEGF therapies (log-rank P = .015).

Conclusion

Intraoperative iCer IPI + NIVO with postoperative iCav NIVO ± IPI up to biweekly doses of 1 mg IPI + 10 mg NIVO is feasible and safe, showing encouraging OS in rHGG patients. ClinicalTrials.gov registration: NCT03233152

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCTLA-4 AntigenNeoplasm Recurrence, LocalNivolumabHumansMaleFemaleMiddle AgedAdultAgedIpilimumabFollow-Up StudiesPrognosisSurvival RateNeoplasm Grading

Stichwörter der Autor:innen

glioblastomahigh-grade gliomaimmune checkpoint inhibitionimmunotherapylocal administration

Substanzen

Programmed Cell Death 1 ReceptorCTLA4 protein, humanImmune Checkpoint InhibitorsCTLA-4 AntigenPDCD1 protein, humanNivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Neurosurgery, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Laboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Genetics, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Pathology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Radiology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.

ORCID-Profile: Johnny Duerinck

Förderung

  • Excellence of Science

Zitieren

APA

Duerinck, J., Lescrauwaet, L., Dirven, I., Del'haye, J., Stevens, L., Geeraerts, X., Vaeyens, F., Geens, W., Brock, S., Vanbinst, A. M., Everaert, H., Caljon, B., Bruneau, M., Lebrun, L., Salmon, I., Kockx, M., Tuyaerts, S., & Neyns, B. (2024). Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. Neuro-Oncology, 26(12), 2208-2221. https://doi.org/10.1093/neuonc/noae177

Vancouver

Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, et al. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. Neuro-Oncology. 2024;26(12):2208-2221. doi:10.1093/neuonc/noae177

BibTeX
@article{Duerinck2024,
  author = {Duerinck, Johnny and Lescrauwaet, Louise and Dirven, Iris and Del'haye, Jacomi and Stevens, Latoya and Geeraerts, Xenia and Vaeyens, Freya and Geens, Wietse and Brock, Stefanie and Vanbinst, Anne-Marie and Everaert, Hendrik and Caljon, Ben and Bruneau, Michaël and Lebrun, Laetitia and Salmon, Isabelle and Kockx, Marc and Tuyaerts, Sandra and Neyns, Bart},
  title = {Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {12},
  pages = {2208--2221},
  doi = {10.1093/neuonc/noae177}
}
Kostenlos starten →